BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,132 filers reported holding BAXTER INTL INC in Q2 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $34,303,817 | -17.9% | 1,023,975 | +4.7% | 0.02% | -25.0% |
Q1 2024 | $41,788,018 | +44.1% | 978,290 | +30.7% | 0.03% | +12.0% |
Q4 2023 | $28,991,674 | +31.1% | 748,552 | +27.6% | 0.02% | +8.7% |
Q3 2023 | $22,115,296 | -10.7% | 586,535 | +8.0% | 0.02% | -8.0% |
Q2 2023 | $24,759,195 | -16.8% | 543,331 | -26.0% | 0.02% | -30.6% |
Q1 2023 | $29,745,003 | -14.1% | 734,716 | +7.8% | 0.04% | -10.0% |
Q4 2022 | $34,637,077 | +17.1% | 681,399 | +26.1% | 0.04% | -16.7% |
Q3 2022 | $29,584,000 | -13.7% | 540,256 | +2.8% | 0.05% | 0.0% |
Q2 2022 | $34,294,000 | -11.3% | 525,717 | +6.7% | 0.05% | +2.1% |
Q1 2022 | $38,680,000 | -26.7% | 492,719 | -19.6% | 0.05% | -4.1% |
Q4 2021 | $52,774,000 | -27.1% | 613,072 | -31.4% | 0.05% | -32.9% |
Q3 2021 | $72,400,000 | +11.0% | 893,298 | +10.8% | 0.07% | +4.3% |
Q2 2021 | $65,230,000 | -4.5% | 806,348 | +0.2% | 0.07% | -12.5% |
Q1 2021 | $68,336,000 | +1.4% | 804,678 | -4.9% | 0.08% | -11.1% |
Q4 2020 | $67,408,000 | +9.1% | 846,575 | +10.2% | 0.09% | -9.1% |
Q3 2020 | $61,770,000 | +28.7% | 768,209 | +37.8% | 0.10% | +7.6% |
Q2 2020 | $47,986,000 | -14.3% | 557,318 | -18.9% | 0.09% | -29.2% |
Q1 2020 | $55,973,000 | +19.5% | 686,802 | +24.9% | 0.13% | +60.5% |
Q4 2019 | $46,848,000 | -3.8% | 549,729 | -1.3% | 0.08% | -11.0% |
Q3 2019 | $48,704,000 | +4.5% | 556,806 | -2.2% | 0.09% | +3.4% |
Q2 2019 | $46,626,000 | +13.8% | 569,310 | +13.0% | 0.09% | +17.3% |
Q1 2019 | $40,955,000 | +45.7% | 503,688 | +17.9% | 0.08% | +44.2% |
Q4 2018 | $28,113,000 | -39.2% | 427,124 | -28.8% | 0.05% | -29.7% |
Q3 2018 | $46,245,000 | -14.0% | 599,894 | -17.7% | 0.07% | -22.1% |
Q2 2018 | $53,785,000 | -14.5% | 728,591 | -24.6% | 0.10% | +1.1% |
Q1 2018 | $62,872,000 | -15.2% | 966,597 | -15.7% | 0.09% | -12.1% |
Q4 2017 | $74,150,000 | -26.8% | 1,147,245 | -29.0% | 0.11% | -34.0% |
Q3 2017 | $101,325,000 | +14.4% | 1,614,978 | +10.4% | 0.16% | -0.6% |
Q2 2017 | $88,552,000 | -3.1% | 1,462,672 | -16.8% | 0.16% | -14.7% |
Q1 2017 | $91,405,000 | +31.9% | 1,757,447 | +12.4% | 0.19% | +17.9% |
Q4 2016 | $69,301,000 | +9.0% | 1,563,039 | +17.0% | 0.16% | +2.5% |
Q3 2016 | $63,595,000 | -29.6% | 1,336,354 | -33.1% | 0.16% | -36.3% |
Q2 2016 | $90,318,000 | +70.3% | 1,997,247 | +54.7% | 0.25% | +65.3% |
Q1 2016 | $53,025,000 | +107.9% | 1,290,781 | +93.0% | 0.15% | +145.9% |
Q4 2015 | $25,507,000 | +28.5% | 668,907 | +10.6% | 0.06% | +22.0% |
Q3 2015 | $19,843,000 | -55.5% | 604,650 | -5.1% | 0.05% | -45.1% |
Q2 2015 | $44,609,000 | -14.8% | 636,915 | -16.7% | 0.09% | -9.9% |
Q1 2015 | $52,374,000 | +1.9% | 764,309 | +9.1% | 0.10% | -5.6% |
Q4 2014 | $51,400,000 | -5.4% | 700,255 | -7.5% | 0.11% | -5.3% |
Q3 2014 | $54,352,000 | +10.5% | 757,274 | +11.4% | 0.11% | +6.6% |
Q2 2014 | $49,203,000 | -18.0% | 680,083 | -16.7% | 0.11% | -25.9% |
Q1 2014 | $59,989,000 | -14.9% | 816,025 | -19.5% | 0.14% | -22.3% |
Q4 2013 | $70,502,000 | +21.5% | 1,014,036 | +14.9% | 0.18% | +15.7% |
Q3 2013 | $58,042,000 | -16.1% | 882,677 | -11.5% | 0.16% | -23.6% |
Q2 2013 | $69,167,000 | +71.4% | 997,806 | +79.6% | 0.21% | +42.5% |
Q1 2013 | $40,356,000 | +40.2% | 555,576 | +28.7% | 0.15% | +31.5% |
Q4 2012 | $28,782,000 | +35.0% | 431,764 | +22.1% | 0.11% | +32.1% |
Q3 2012 | $21,317,000 | -16.7% | 353,731 | -26.2% | 0.08% | -27.6% |
Q2 2012 | $25,596,000 | +121.3% | 479,475 | +147.8% | 0.12% | +127.5% |
Q1 2012 | $11,564,000 | – | 193,466 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Point | 36,000,000 | $2,658,240,000 | 18.52% |
SECTOR GAMMA AS | 721,058 | $53,243,000 | 8.85% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,747,061 | $202,843,000 | 5.38% |
Veritas Asset Management LLP | 8,852,005 | $653,632,000 | 5.36% |
Knowledge Leaders Capital, LLC | 79,384 | $5,862,000 | 4.39% |
HealthCor Management, L.P. | 1,800,000 | $132,912,000 | 4.22% |
Progressive Investment Management Corp | 79,282 | $5,854,000 | 3.78% |
13D Management LLC | 200,318 | $14,791,000 | 3.77% |
ARGENT CAPITAL MANAGEMENT LLC | 1,288,236 | $95,123,000 | 3.42% |
Chiron Investment Management, LLC | 612,787 | $45,248,000 | 3.12% |